Nicholas Moore - Gilead Sciences Independent Director

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;padding-top: 25px;;'>GS</div>
GILD -- USA Stock  

Trending

  Director
Mr. Nicholas G. Moore is no longer Independent Director of Gilead Sciences Inc., effective May 2018. He joined our Board in 2004. Mr. Moore is the retired global Chairman of PricewaterhouseCoopers LLP, a professional services firm formed in July 1998 by the merger of Coopers Lybrand and Price Waterhouse. Prior to the merger, Mr. Moore was elected Chairman and Chief Executive Officer of Coopers Lybrand in 1994 and Coopers Lybrand International in 1997. Mr. Moore is a director of Bechtel Group, Inc. and previously served as lead independent director of NetApp and director and chairman of the audit committee at Wells Fargo. He has also served as Chairman of the Board of Trustees of St. Marys College of California
Age: 74  Director Since 2004      
650 574-3000  www.gilead.com
Moore is an inactive member of the American Institute of Certified Public Accountants, the California Bar Association and the California and New York Society of Certified Public Accountants.

Nicholas Moore Latest Insider Activity

Gilead Sciences Management Efficiency

Gilead Sciences has return on total asset (ROA) of 0.0013 % which means that it generated profit of $0.0013 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 0.0034 % meaning that it created $0.0034 on every $100 dollars invested by stockholders. Gilead Sciences management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. The current year Return on Investment is expected to grow to 9.18. The current year Return on Average Assets is expected to grow to 0.13Gilead Sciences Total Assets Per Share are expected to significantly increase based on the last few years of reporting. The last year's Total Assets Per Share were at 48.68. The current year Asset Turnover is expected to grow to 0.43, whereas Current Assets are expected to decline to about 1.2 B. The current year Tax Liabilities is expected to grow to about 6.6 B, whereas Total Liabilities is expected to decline to about 34.3 B.
The company currently holds 28.84 B in liabilities with Debt to Equity (D/E) ratio of 139.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Gilead Sciences has Current Ratio of 3.0 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Marvinder BangaGlaxoSmithKline PLC
2016
Tim JacksonSmithAstrazeneca PLC
2015
Graham ChipchaseAstrazeneca PLC
2019
Vicki SatoBristol Myers Squibb
2017
Anne MulcahyJohnson Johnson
2012
Carina LazaroGrifols S A
2015
Kathi SeifertEli Lilly And
1995
Mary BeckerleJohnson Johnson
2015
Sherilyn McCoyAstrazeneca PLC
2017
Inge ThulinMerck Company
2018
William PerezJohnson Johnson
2007
Karen VousdenBristol Myers Squibb
2018
Michael EskewEli Lilly And
2008
Erik FyrwaldEli Lilly And
2005
Peter WendellMerck Company
2003
Stacey CartwrightGlaxoSmithKline PLC
2011
Urs RohnerGlaxoSmithKline PLC
2015
Philip HamptonGlaxoSmithKline PLC
2015
JeanPhilippe CourtoisAstrazeneca PLC
2008
Ronald WilliamsJohnson Johnson
2011
Weiying WangAstrazeneca PLC
2019

Company Summary

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company was founded in 1987 and is headquartered in Foster City, California. Gilead Sciences operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 11800 people.Gilead Sciences (GILD) is traded on BATS Exchange in USA. It is located in 333 Lakeside Drive, Foster City, CA 94404, United States and employs 11,800 people. Gilead Sciences is listed under Pharmaceutical Products category by Fama And French industry classification.

Gilead Sciences Leadership Team

Kathleen Watson, Executive Vice President - Human Resources
John McHutchison, Executive Vice President - Clinical Research
Andrew Cheng, Executive Vice President - HIV Therapeutics and Development Operations
John Martin, Chairman and CEO
Andrew Dickinson, Executive Vice President - Corporate Development and Strategy
Gayle Wilson, Independent Director
Daniel ODay, Chairman of the Board, CEO
Jacqueline Barton, Director
Brett Pletcher, Executive VP and General Counsel
William Lee, Executive Vice President - Research
John Madigan, Independent Director
Martin Silverstein, Executive Vice President - Strategy
Kevin Lofton, Independent Director
Paul Carter, Executive Vice President - Commercial Operations
Gregg Alton, Executive VP of Corporate and Medical Affairs and Secretary
Diana Brainard, Senior Vice President HIV and Emerging Viral Infections
Carla Hills, Independent Director
John Cogan, Lead Independent Director
John Milligan, Pres and COO
Nicholas Moore, Independent Director
James Meyers, Executive Vice President - Worldwide Commercial Operations
Katie Watson, Executive Vice President of Human Resources
Kelly Kramer, Director
Johanna Mercier, Chief Commercial Officer
Jyoti Mehra, Executive Vice President of Human Resources
Laura Hamill, Executive Vice President - Worldwide Commercial Operations
Robin Washington, CFO and Executive VP
Norbert Bischofberger, Chief Scientific Officer and Executive VP of RandD
Per WoldOlsen, Independent Director
Harish Manwani, Director
Taiyin Yang, Executive Vice President - Pharmaceutical Development and Manufacturing
Kevin Young, COO
Etienne Davignon, Independent Director
Richard Whitley, Independent Director

Stock Performance Indicators

Did you try this?

Run Insider Screener Now

   

Insider Screener

Find insiders across different sectors to evaluate their impact on performance
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Risk vs Return Analysis. Please also try Instant Ratings module to determine any equity ratings based on digital recommendations. macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page